



Natural Killer-cell Immunoglobulin-like Receptor genotyping methods(software)

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI : Prof. Jacob Shujui Hsu

Department of Medical Genomics and Proteomics,
National Taiwan U.

Experience:

An interesting **photo** related to
your technology
(be careful not to disclose key
technology)

Market Needs:

Our Technology:

Companion Diagnostics for Killer-cell Immunoglobulin-like Receptor vs. Human Leukocyte Antigen (KIR-HLA) Gene-Targeted NK Cell Therapy in Acute Myeloid Leukemia (AML): A next-generation, integrated medical device suite enabling precise, safe, and efficient delivery of KIR-HLA gene-targeted NK cell therapy for AML. The focus is on automation, AI-driven analytics, and seamless clinical integration to maximize therapeutic impact and patient safety.

Strength:

Help clinics, hospitals, biopharmas, and biotechs to develop NK/NK-T/T-cell-based therapies to match immunogenomics in donor/receiver allogeneic cells, improve relapse-free survival rate in 6 months, and reduce or control graft-versus-host diseases (GvHD) to level 1 using our genomic-allele typing & matching services

Competing Products:

Intellectual Properties:

1st time application

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU

Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.